These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 8242478)

  • 1. [Carnitine levels in muscle in mice with hyperammonemia: effect of treatment with sodium benzoate].
    Michalak A; Qureshi IA
    Can J Physiol Pharmacol; 1993 Jul; 71(7):439-46. PubMed ID: 8242478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Profile of hepatic and muscular acylcarnitines in chronically hyperammonemic mice after an acute treatment with sodium benzoate: dose-response study].
    Michalak A; Qureshi IA
    Ann Biol Clin (Paris); 1993; 51(10-11):879-85. PubMed ID: 8210064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue acylcarnitine and acyl-coenzyme A profiles in chronically hyperammonemic mice treated with sodium benzoate and supplementary L-carnitine.
    Michalak A; Qureshi IA
    Biomed Pharmacother; 1995; 49(7-8):350-7. PubMed ID: 8562862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma and urinary levels of carnitine in different experimental models of hyperammonemia and the effect of sodium benzoate treatment.
    Michalak A; Qureshi IA
    Biochem Med Metab Biol; 1990 Apr; 43(2):163-74. PubMed ID: 2346672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developmental deficiency of the cholinergic system in congenitally hyperammonemic spf mice: effect of acetyl-L-carnitine.
    Ratnakumari L; Qureshi IA; Maysinger D; Butterworth RF
    J Pharmacol Exp Ther; 1995 Jul; 274(1):437-43. PubMed ID: 7616428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hypocarnitinemia in patients affected by a primary defect of ammonia metabolism treated with sodium benzoate].
    Michalak A; Lambert MA; Dallaire L; Melançon SB; Laframboise R; Lemieux B; Qureshi IA
    Diabete Metab; 1990; 16(3):226-33. PubMed ID: 2210018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of sodium benzoate on cerebral and hepatic energy metabolites in spf mice with congenital hyperammonemia.
    Ratnakumari L; Qureshi IA; Butterworth RF
    Biochem Pharmacol; 1993 Jan; 45(1):137-46. PubMed ID: 8424807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of L-carnitine on cerebral and hepatic energy metabolites in congenitally hyperammonemic sparse-fur mice and its role during benzoate therapy.
    Ratnakumari L; Qureshi IA; Butterworth RF
    Metabolism; 1993 Aug; 42(8):1039-46. PubMed ID: 8102193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Free and esterified coenzyme A in the liver and muscles of chronically hyperammonemic mice treated with sodium benzoate.
    Michalak A; Qureshi IA
    Biochem Mol Med; 1995 Apr; 54(2):96-104. PubMed ID: 8581365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of sodium benzoate and sodium phenylacetate on brain serotonin turnover in the ornithine transcarbamylase-deficient sparse-fur mouse.
    Batshaw ML; Hyman SL; Coyle JT; Robinson MB; Qureshi IA; Mellits ED; Quaskey S
    Pediatr Res; 1988 Apr; 23(4):368-74. PubMed ID: 3374991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and inducibility of the hepatic and renal hippurate-synthesizing system in sparse-fur (spf) mutant mice with ornithine transcarbamylase deficiency.
    Qureshi IA; Lebel S; Letarte J
    Biochem Int; 1989 Sep; 19(3):657-66. PubMed ID: 2818615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction between murine spf-ash mutation and genetic background yields different metabolic phenotypes.
    Marini JC; Erez A; Castillo L; Lee B
    Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1764-71. PubMed ID: 17925451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potentiation of ammonia toxicity by sodium benzoate is prevented by L-carnitine.
    O'Connor JE; Costell M; Grisolía S
    Biochem Biophys Res Commun; 1987 Jun; 145(2):817-24. PubMed ID: 3593373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status.
    Hamed SA; Abdella MM
    Epilepsy Res; 2009 Sep; 86(1):32-41. PubMed ID: 19446440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperammonemia increases sensitivity to LPS.
    Marini JC; Broussard SR
    Mol Genet Metab; 2006 Jun; 88(2):131-7. PubMed ID: 16497529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of hyperammonemia on the levels of carnitine in mice.
    Costell M; Míguez MP; O'Connor JE; Grisolía S
    Neurology; 1987 May; 37(5):804-8. PubMed ID: 3574681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of transported glycine in the conjugation of sodium benzoate in spf mutant mice with ornithine transcarbamylase deficiency.
    Qureshi I; Rouleau T; Letarte J; Ouellet R
    Biochem Int; 1986 Jun; 12(6):839-46. PubMed ID: 3091026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benzoate therapy and carnitine deficiency in non-ketotic hyperglycinemia.
    Van Hove JL; Kishnani P; Muenzer J; Wenstrup RJ; Summar ML; Brummond MR; Lachiewicz AM; Millington DS; Kahler SG
    Am J Med Genet; 1995 Dec; 59(4):444-53. PubMed ID: 8585564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure of L-carnitine to protect mice against hyperammonemia induced by ammonium acetate or urease injection.
    Deshmukh DR; Singh KR; Meert K; Deshmukh GD
    Pediatr Res; 1990 Sep; 28(3):256-60. PubMed ID: 2235123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Partial pyruvate decarboxylase deficiency with profound lactic acidosis and hyperammonemia: responses to dichloroacetate and benzoate.
    McCormick K; Viscardi RM; Robinson B; Heininger J
    Am J Med Genet; 1985 Oct; 22(2):291-9. PubMed ID: 4050860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.